Glaukos Corporation to Release Fourth Quarter and Full Year 2020 Financial Results after Market Close on February 25

Rhea-AI Summary

Glaukos Corporation (NYSE: GKOS) will announce its fourth quarter and full year 2020 financial results on February 25, 2021, after market closure. A conference call to discuss these results will take place at 1:30 p.m. PST (4:30 p.m. EST) on the same day. Investors can access the live webcast through the company’s website. Glaukos specializes in innovative treatments for glaucoma and other ocular conditions, having pioneered Micro-Invasive Glaucoma Surgery (MIGS) with devices such as the iStent® and iStent inject®.

Positive

• Pioneering Micro-Invasive Glaucoma Surgery (MIGS) with a strong product portfolio.
• Recent launch of the iStent inject W device in October 2020.

Negative

• None.

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release fourth quarter and full year 2020 financial results after the market close on Thursday, February 25, 2021. The company’s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PST (4:30 p.m. EST) on February 25, 2021.

A link to the live webcast will be available on the company’s website at http://investors.glaukos.com. To participate in the conference call, please dial 833-231-8262 (U.S.) or 647-689-4107 (International) and enter Conference ID 4167849. A replay will be archived on the company’s website following completion of the call.

About Glaukos

Glaukos (www.glaukos.com) is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. The company pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm. Glaukos launched the iStent^®, its first MIGS device, in the United States in July 2012, its next-generation iStent inject^® device in the United States in September 2018, and most recently, the iStent inject W device in October 2020. In corneal health, Glaukos’ proprietary suite of single-use, bio-activated pharmaceuticals are designed to strengthen, stabilize and reshape the cornea through a process called corneal collagen cross-linking to treat corneal ectatic disorders and correct refractive conditions. Glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of micro-scale surgical and pharmaceutical therapies in glaucoma, corneal health and retinal disease.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210204005172/en/

FAQ

When will Glaukos release its fourth quarter 2020 financial results?

Glaukos will release its fourth quarter 2020 financial results on February 25, 2021, after the market close.

What time is the Glaukos conference call scheduled for?

The conference call to discuss the results will occur at 1:30 p.m. PST (4:30 p.m. EST) on February 25, 2021.

How can I access the Glaukos conference call?

Investors can participate in the conference call by dialing 833-231-8262 (U.S.) or 647-689-4107 (International) and entering Conference ID 4167849.

What innovative products has Glaukos launched?

Glaukos has launched several products including the iStent® in July 2012, the iStent inject® in September 2018, and the iStent inject W in October 2020.